Inventor · disambiguated record
Niall O'Donnell
Also filed as: O'DONNELL NIALL
10 granted patents·20 pending applications·16 citations·filing 2009–2025
86Inventor score
Files withLUMENA PHARMACEUTICALS INC7SHIRE HUMAN GENETIC THERAPIES6DEAN NICHOLAS M5EXCALIARD PHARMACEUTICALS INC4LUMENA PHARMACEUTICALS LLC4
Top patents by PatentIndex Score
30 records- 0189US11229661B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Jan 25, 2022·2 cites·17 claims
- 0287US2025282808A1Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseSHIRE HUMAN GENETIC THERAPIES·Filed 2024·Application pending·0 cites
- 0386US10512657B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesLUMENA PHARMACEUTICALS LLC·Filed 2016·Granted Dec 24, 2019·6 cites·17 claims
- 0485US2025281482A1Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2025·Application pending·0 cites
- 0583US8252762B2Antisense oligonucleotides directed against connective tissue growth factor and uses thereofDEAN NICHOLAS M·Filed 2009·Granted Aug 28, 2012·5 cites·25 claims
- 0682US12350267B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Granted Jul 8, 2025·0 cites·20 claims
- 0782US12145959B2Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Granted Nov 19, 2024·0 cites·21 claims
- 0879US11376251B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2021·Granted Jul 5, 2022·0 cites·19 claims
- 0976US9096851B2Antisense oligonucleotides directed against connective tissue growth factor and uses thereofDEAN NICHOLAS M·Filed 2012·Granted Aug 4, 2015·2 cites·51 claims
- 1068US2024016809A1Use of ppar-delta agonists in the treatment of diseaseRENEO PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1165US9173894B2Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)DEAN NICHOLAS M·Filed 2012·Granted Nov 3, 2015·1 cites·27 claims
- 1264US2020190521A1Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)DEAN NICHOLAS M·Filed 2019·Application pending·0 cites
- 1363US2020207797A1Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseLUMENA PHARMACEUTICALS LLC·Filed 2019·Application pending·0 cites
- 1462US2013338093A1Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver DiseasesLUMENA PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1561US2013109671A1Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver DiseasesLUMENA PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1661US2017368085A1Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesLUMENA PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 1761US2014243281A1Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesLUMENA PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1860US2019169217A1Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseLUMENA PHARMACEUTICALS LLC·Filed 2018·Application pending·0 cites
- 1959US8772260B2Methods for inhibiting expression of connective tissue growth factorDEAN NICHOLAS M·Filed 2012·Granted Jul 8, 2014·0 cites·27 claims
- 2059US2014323412A1Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseLUMENA PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2159US2013108573A1Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver DiseaseLUMENA PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2259US2019323013A1Antisense oligonucleotides directed against connective tissue growth factor and uses thereofEXCALIARD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2355US2017335329A1Antisense oligonucleotides directed against connective tissue growth factor and uses thereofEXCALIARD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2452US9688987B2Antisense oligonucleotides directed against connective tissue growth factor and uses thereofEXCALIARD PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·0 cites·59 claims
- 2546US2022370467A1Using of a ppar-delta agonist in the treatment of kidney diseaseRENEO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2644US2022117972A1Use of ppar-delta agonists in the treatment of mitochondrial myopathyRENEO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2744US2022023306A1Use of a ppar-delta agonist in the treatment of fatty acid oxidation disorders (faod)RENEO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2843US2014271734A1Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux diseaseLUMENA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2943US2014275090A1Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel diseaseLUMENA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3037US2017022501A1Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)EXCALIARD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Niall O'Donnell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →